Publication details

Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer

Authors

FALTEJSKOVÁ Petra BOČÁNEK Ondřej ŠACHLOVÁ Milana SVOBODA Marek KISS Igor VYZULA Rostislav SLABÝ Ondřej

Year of publication 2012
Type Article in Periodical
Magazine / Source Cancer Biomarkers
MU Faculty or unit

Central European Institute of Technology

Citation
Doi http://dx.doi.org/10.3233/CBM-130308
Field Oncology and hematology
Keywords microRNAs; serum; colorectal cancer; biomarkers
Description BACKGROUND: Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the world. Therefore, there is a high demand for cost-effective and non-invasive biomarkers that would enable an early detection of asymptomatic and curable disease with high sensitivity and specificity. OBJECTIVE: The main objective of this study was to investigate the potential of circulating miRNAs as biomarkers of CRC. METHODS: Total RNA enriched for small RNAs was isolated from 100~sera of patients with CRC and 30 sera of healthy donors. The expression levels of miR-17-3p, miR-29a, miR-92a and miR-135b were determined using quantitative real-time PCR. The average expression levels of particular miRNAs were normalized to miR-16 levels and statistically evaluated. RESULTS: Using Mann-Whitney U test, no significant differences were observed in miR-17-3p (P=0.18), miR-29a (P=0.14) and miR-92a (P=0.60) levels between sera of CRC patients and controls. The levels of miR-135b in serum were too low to be quantified accurately. Subsequently, we tried to correlate expression levels of analyzed miRNAs to clinical-pathological features of CRC patients. Only levels of mir-29a were correlated with the clinical stage (P=0.04). Expression levels of the other miRNAs were correlated neither with the clinical stage, nor with the grade. CONCLUSIONS: Interestingly, our results are contradictory to previous studies performed on the CRC patients from Chinese population, providing an evidence against usage of serum miR-17-3p, miR-29a, miR-92a and miR-135b as new biomarkers for early detection of CRC.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info